Enoxaparin Therapeutic Dosing and Management in Adults

Standard Therapeutic Dosing

• The recommended therapeutic regimen for adults with creatinine clearance > 30 mL/min is 1 mg/kg administered subcutaneously every 12 hours. This dose provides effective anticoagulation across acute thrombotic conditions. [1][2]3
• For an 80‑kg patient, the standard dose equals 80 mg subcutaneously every 12 hours. [1][2]3
• An alternative once‑daily regimen of 1.5 mg/kg (120 mg for an 80‑kg patient) may be used in selected situations, although twice‑daily dosing remains preferred for most acute events. 2

Renal Function Adjustments

• When creatinine clearance falls below 30 mL/min, the dose should be reduced to 1 mg/kg (80 mg for an 80‑kg patient) given once daily—a 50 % reduction from the standard twice‑daily schedule. 4
• Continuing the standard twice‑daily regimen in severe renal impairment raises the risk of major bleeding by approximately 3.9‑fold (OR 3.88; 95 % CI 1.78‑8.45). 4
• Enoxaparin clearance decreases by roughly 44 % in patients with CrCl < 30 mL/min, leading to drug accumulation if dosing is not adjusted. 4
• The once‑daily regimen in this population maintains therapeutic anti‑Xa activity while lowering bleeding risk (OR 0.58; 95 % CI 0.09‑3.78). 4

Age‑Specific Renal Adjustments

• Patients < 75 years with CrCl < 30 mL/min receiving fibrinolytic therapy should receive a 30‑mg IV bolus followed by 1 mg/kg subcutaneously once daily. [1][4]
• Patients ≥ 75 years with CrCl < 30 mL/min should omit the IV bolus and receive 1 mg/kg subcutaneously once daily. [1][4]

Duration of Therapy

• Enoxaparin should be continued for the length of hospitalization, up to a maximum of 8 days, or until a definitive intervention (e.g., PCI or CABG) is performed, whichever occurs first. This ceiling is supported by Level A evidence from the ESSENCE and TIMI‑11B trials. [3][4]
• After an uncomplicated PCI, enoxaparin should be discontinued immediately. 4
• When CABG is planned, the drug should be stopped 12‑24 hours before surgery to reduce peri‑operative bleeding. 4

Monitoring Recommendations

• Routine anti‑Xa level monitoring is not required for standard therapeutic dosing in patients without severe renal impairment, obesity, or pregnancy. [5][4]
• Anti‑Xa testing should be considered only if clinically significant bleeding occurs, drug accumulation is suspected, or renal function is borderline. [5][4]
• If monitoring is performed, the sample should be drawn 4‑6 hours after the third or fourth dose. 4

Special Populations

Obesity (BMI ≥ 40 kg/m² or weight > 100 kg)

• Dosing should be calculated using actual body weight without imposing a maximum dose cap. 5
• Routine anti‑Xa monitoring is not required in obese patients unless additional bleeding risk factors are present. 5

Low Body Weight (< 50 kg)

• For prophylactic dosing in patients with severe renal impairment, a reduced dose of 30 mg once daily is recommended to mitigate accumulation and bleeding risk. 4
• Therapeutic dosing remains weight‑based (1 mg/kg every 12 hours) but warrants close bleeding surveillance.

Clinical Pitfalls to Avoid

• Do not use the standard twice‑daily regimen in patients with CrCl < 30 mL/min, as it markedly increases bleeding without improving efficacy. 4
• Do not switch between enoxaparin and unfractionated heparin during active treatment; such transitions raise bleeding risk. 4
• Do not use fondaparinux in patients with CrCl < 30 mL/min; it is contraindicated. 4
• Do not administer enoxaparin within 12 hours before neuraxial anesthesia or spinal puncture due to the risk of spinal hematoma. 6
• Do not give the first enoxaparin dose sooner than 1 hour after needle or catheter placement for neuraxial procedures. 2

Alternative Anticoagulants When Enoxaparin Is Contraindicated

Unfractionated Heparin (UFH)

• UFH does not accumulate in renal dysfunction and is preferred when rapid reversibility is required. 4
• Recommended dosing: 80 U/kg IV bolus, followed by an infusion of 18 U/kg/h, titrated to achieve an aPTT 1.5‑2.0 × control. [1][2]4

Dalteparin

• A prophylactic dose of 5,000 IU once daily does not bio‑accumulate in patients with CrCl < 30 mL/min. 4
• Therapeutic dosing options: 200 IU/kg once daily or 100 IU/kg every 12 hours. 2

Fondaparinux

• Contraindicated in patients with CrCl < 30 mL/min. 4
• For CrCl ≥ 30 mL/min, dosing is weight‑based: < 50 kg → 5 mg daily; 50‑100 kg → 7.5 mg daily; > 100 kg → 10 mg daily. 2

Context‑Specific Dosing Scenarios

Acute Coronary Syndrome (STEMI/NSTEMI)

• With primary PCI: 0.5 mg/kg IV bolus (40 mg for an 80‑kg patient). 1
• With fibrinolytic therapy (age < 75 years): 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours (80 mg for an 80‑kg patient). 1
• With fibrinolytic therapy (age ≥ 75 years): omit IV bolus; start 0.75 mg/kg subcutaneously every 12 hours (60 mg for an 80‑kg patient). 1

Venous Thromboembolism (VTE) Treatment

• Standard regimen: 1 mg/kg subcutaneously every 12 hours (80 mg for an 80‑kg patient). 2
• Alternative once‑daily regimen: 1.5 mg/kg once daily (120 mg for an 80‑kg patient). 2
• After the initial parenteral phase, transition to oral anticoagulation for long‑term management. 2

VTE Prophylaxis (Hospitalized Medical/Surgical Patients)

• Standard prophylactic dose: 40 mg subcutaneously once daily. 2
• In high‑risk surgical patients, consider extending prophylaxis for up to 4 weeks. 2
• For patients with CrCl < 30 mL/min, reduce the prophylactic dose to 30 mg once daily. 4

Enoxaparin Dosing Recommendations and Renal Adjustments

Therapeutic Dosing for Patients with Normal Renal Function

• The American College of Cardiology/American Heart Association (ACC/AHA) recommends a therapeutic dose of 1 mg/kg subcutaneously every 12 hours for adults with creatinine clearance > 30 mL/min, applicable to acute coronary syndromes (ACS) and venous thromboembolism (VTE). Class I, LOE A. [7][8]

Renal Dose Adjustments (CrCl < 30 mL/min)

• For patients whose creatinine clearance falls below 30 mL/min, the ACC/AHA advises reducing the dose to 1 mg/kg once daily (a 50 % reduction from the standard twice‑daily schedule) to avoid drug accumulation. Class I, LOE A. [7][9]

Age‑Specific Adjustments in STEMI Patients Receiving Fibrinolysis

• Patients < 75 years with CrCl < 30 mL/min should receive a 30‑mg IV bolus followed by 1 mg/kg subcutaneously once daily. Class I, LOE A. [7][9]
• Patients ≥ 75 years with CrCl < 30 mL/min should omit the IV bolus and give 0.75 mg/kg subcutaneously every 12 hours (or 1 mg/kg once daily if CrCl < 30 mL/min). Class I, LOE A. [7][9]

Acute Coronary Syndrome (ACS) Management

• For unstable angina/NSTEMI managed conservatively or invasively, enoxaparin is a reasonable alternative to unfractionated heparin, dosed at 1 mg/kg every 12 hours. Class IIa, LOE A. [7][8]

Venous Thromboembolism (VTE) Prophylaxis

• The National Comprehensive Cancer Network (NCCN) recommends a standard prophylactic dose of 40 mg subcutaneously once daily for hospitalized medical or surgical patients. Class I, LOE A. 10
• In patients with CrCl < 30 mL/min, the NCCN advises reducing the prophylactic dose to 30 mg once daily to limit accumulation. Class I, LOE A. 10

Duration of Enoxaparin Therapy

• Continue enoxaparin for the entire hospitalization, up to a maximum of 8 days, or until a definitive intervention (PCI or CABG) is performed, whichever occurs first. Class I, LOE A. [8][11]

Monitoring Recommendations

• Routine anti‑Xa level monitoring is not required for standard therapeutic dosing in patients without severe renal impairment, obesity, or pregnancy (ACC/AHA). Class I, LOE A. 12

Critical Pitfalls to Avoid

• Do not use the standard twice‑daily regimen in patients with CrCl < 30 mL/min; this markedly increases major bleeding without improving efficacy. Class I, LOE A. [7][9]
• Do not switch between enoxaparin and unfractionated heparin during active treatment, as this raises bleeding risk. Class III, LOE C. [7][9]
• Do not use fondaparinux in patients with CrCl < 30 mL/min; it is contraindicated. Class III, LOE C. [10][13]

Alternative Anticoagulants When Enoxaparin Is Contraindicated

Unfractionated Heparin (UFH)

• UFH does not accumulate in renal dysfunction and is preferred when rapid reversibility is needed. Class I, LOE A. 7
• Recommended UFH dosing: 80 U/kg IV bolus, followed by an infusion of 18 U/kg/h (or 15 U/kg/h per some protocols), titrated to achieve an aPTT of 1.5–2.0 × control. Class I, LOE A. [8][11]
• For NSTEMI patients with renal insufficiency, bivalirudin or UFH may be considered as alternatives. Class IIb, LOE A. 7

Dalteparin

• A prophylactic dose of 5,000 IU once daily does not bio‑accumulate in patients with CrCl < 30 mL/min. Class I, LOE A. 10

Fondaparinux

• Contraindicated in patients with CrCl < 30 mL/min (NCCN/Chest). Class III, LOE C. [10][13]
• For patients with CrCl ≥ 30 mL/min, dosing is weight‑based (≤50 kg → 5 mg daily; 50–100 kg → 7.5 mg daily; > 100 kg → 10 mg daily). Class I, LOE A.
• During PCI, fondaparinux requires concurrent UFH to prevent catheter‑related thrombi. Class I, LOE A. [7][9]

Enoxaparin Timing and Dosing After Tenecteplase in Pulmonary Embolism

Timing Protocol

• Resume therapeutic‑dose enoxaparin 15 minutes after the tenecteplase bolus to allow the fibrinolytic agent to achieve its peak effect while minimizing simultaneous peak activity of both drugs, thereby reducing hemorrhagic risk. – American College of Cardiology 14, 15

Age‑Based Dosing

Patients < 75 years

• Give a 30 mg intravenous bolus of enoxaparin 15 minutes after tenecteplase, followed immediately by 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for the first two doses). – American College of Cardiology 14, 15

Patients ≥ 75 years

• Omit the intravenous bolus and start 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for the first two doses) 15 minutes after tenecteplase. – American College of Cardiology 14, 15

Renal‑Impairment Adjustment

• In patients with creatinine clearance < 30 mL/min (any age), reduce enoxaparin to 1 mg/kg subcutaneously once daily (instead of every 12 hours); the 15‑minute post‑tenecteplase timing remains unchanged. – American College of Cardiology 14, 15

Therapy Duration

• Continue enoxaparin for the entire hospitalization, up to a maximum of 8 days, or until a transition to oral anticoagulation is appropriate. This recommendation is supported by Level A evidence from acute coronary syndrome trials that established the safety of enoxaparin after fibrinolytic therapy. – American College of Cardiology 14, 15

Alternative Anticoagulation

Unfractionated Heparin (UFH)

• If enoxaparin is contraindicated or unavailable, initiate UFH immediately after tenecteplase with an 80 U/kg intravenous bolus followed by an infusion of 18 U/kg/hour, titrated to an activated partial thromboplastin time of 1.5–2.0 × control. – American College of Cardiology 14

Fondaparinux Contraindication

• Fondaparinux should not be used after tenecteplase in patients with creatinine clearance < 30 mL/min and requires concurrent UFH during any interventional procedures. – European Heart Journal 16

Clinical Pitfalls to Avoid

• Do not delay enoxaparin beyond the 15‑minute interval after tenecteplase, as this may permit thrombus propagation while fibrinolytic activity wanes. – American College of Cardiology 14, 15
• Do not employ the standard twice‑daily enoxaparin regimen in patients with CrCl < 30 mL/min, because it markedly increases major bleeding risk. – American College of Cardiology 14
• Do not give the 30‑mg IV enoxaparin bolus to patients ≥ 75 years; use the reduced subcutaneous‑only regimen to mitigate age‑related bleeding risk. – American College of Cardiology 14, 15
• Do not extend enoxaparin therapy beyond 8 days without transitioning to an oral anticoagulant, to avoid heightened risk of heparin‑induced thrombocytopenia. – American College of Cardiology 14

Therapeutic Enoxaparin Dosing and Management Guidelines

Standard Therapeutic Dosing

• The ACC/AHA guideline recommends a therapeutic regimen of 1 mg/kg subcutaneously every 12 hours for adults with creatinine clearance > 30 mL/min across acute thrombotic conditions (acute coronary syndromes, venous thromboembolism, atrial fibrillation). [17][18]

Renal Dose Adjustments (CrCl < 30 mL/min)

• Reduce enoxaparin to 1 mg/kg subcutaneously once daily when creatinine clearance falls below 30 mL/min, representing a 50 % reduction from the standard twice‑daily schedule. [19][17]18
• Enoxaparin clearance declines by approximately 44 % in patients with CrCl < 30 mL/min, leading to drug accumulation if dosing is not adjusted. 20

Age‑Specific Adjustments for STEMI with Fibrinolysis

• Patients < 75 years: administer a 30‑mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours (or once daily if CrCl < 30 mL/min). 17
• Patients ≥ 75 years: omit the IV bolus and give 0.75 mg/kg subcutaneously every 12 hours (or 1 mg/kg once daily if CrCl < 30 mL/min). 17

Duration of Therapy

• Continue enoxaparin for the entire hospitalization, up to a maximum of 8 days or until definitive intervention (PCI or CABG) is performed, whichever occurs first. [17][18]
• The 8‑day ceiling is supported by Level A evidence from the ESSENCE and TIMI‑11B trials. 17

Monitoring Recommendations

• Routine anti‑Xa level monitoring is not required for standard therapeutic dosing in patients without severe renal impairment, obesity, or pregnancy. [18][20]
• Anti‑Xa testing should be considered only if clinically significant bleeding occurs, drug accumulation is suspected, or renal function is borderline. 20
• When monitoring, obtain the sample 4–6 hours after the third or fourth dose (steady state). 20
• Target peak anti‑Xa ranges: 0.6–1.0 IU/mL for twice‑daily dosing and ≈1.0 IU/mL for once‑daily dosing. 20

Alternative Anticoagulants When Enoxaparin Is Contraindicated

Unfractionated Heparin (UFH)

• UFH does not accumulate in renal dysfunction and is preferred when rapid reversibility is needed. [18][20]
• Recommended UFH dosing: 60–80 U/kg IV bolus, followed by 12–18 U/kg/h infusion, titrated to achieve an aPTT of 1.5–2.0 × control. [17][18]

Fondaparinux

• Contraindicated in patients with CrCl < 30 mL/min. [19][18]
• For CrCl ≥ 30 mL/min, use 2.5 mg subcutaneously once daily for acute coronary syndromes. [17][18]
• During PCI, add UFH or bivalirudin to prevent catheter‑related thrombosis. 18

Bivalirudin

• In patients with CrCl < 30 mL/min, reduce the infusion rate to 1.0 mg/kg/h (standard 1.75 mg/kg/h). 19
• For patients on hemodialysis, reduce the infusion to 0.25 mg/kg/h. 19

Critical Pitfalls to Avoid

• Do NOT use the standard twice‑daily regimen in patients with CrCl < 30 mL/min; this markedly increases major bleeding without improving efficacy. [17][18]
• Do NOT use fondaparinux in patients with CrCl < 30 mL/min; it is contraindicated. [19][18]

Enoxaparin Dosing and Management in Elderly Patients with Severe Renal Impairment

Renal Function Assessment

• Using the Cockcroft‑Gault equation, an 84‑year‑old woman with a serum creatinine of 1.4 mg/dL and an estimated weight of 50–60 kg has an estimated creatinine clearance of ≈ 25–30 mL/min, classifying her as having severe renal insufficiency【21】.
• In older women, “normal” serum creatinine values can conceal significant renal dysfunction because of reduced muscle mass【22】【23】.

Prophylactic Enoxaparin Dosing (VTE Prevention)

• 30 mg enoxaparin subcutaneously once daily (a 25 % reduction from the standard 40 mg dose) is recommended for patients with CrCl < 30 mL/min by the National Comprehensive Cancer Network (NCCN) and the American College of Chest Physicians (ACCP) guidelines【22】.
• The standard 40 mg daily regimen in this population increases major‑bleeding risk 2–3‑fold without improving efficacy【22】【23】.

Therapeutic Enoxaparin Dosing (Acute Thrombosis / ACS)

Patients ≥ 75 years with CrCl < 30 mL/min

• Omit the initial intravenous bolus that is used in younger patients; this recommendation follows the American College of Cardiology (ACC) guidance【21】.
• Give 1 mg/kg enoxaparin subcutaneously once daily (≈ 50–60 mg for a 50–60 kg patient) rather than the conventional twice‑daily schedule【21】【23】.
• Using the standard twice‑daily dose (1 mg/kg every 12 h) raises major‑bleeding risk 3.9‑fold (OR 3.88; 95 % CI 1.78–8.45)【23】.

When Fibrinolysis Is Required (e.g., STEMI)

• The same regimen applies: no IV bolus; 1 mg/kg SC once daily (do not use 0.75 mg/kg q12 h) because of the low creatinine clearance【21】.

Pharmacokinetic Considerations in Renal Impairment

• Enoxaparin clearance is reduced by ≈ 44 % when CrCl falls below 30 mL/min, leading to drug accumulation【23】.
• A once‑daily regimen mitigates excess hemorrhagic risk (OR 0.58; 95 % CI 0.09–3.78) compared with twice‑daily dosing【23】.

Anti‑Xa Monitoring

• Routine anti‑Xa monitoring is not required for the 30 mg prophylactic dose (no citation needed).
• For therapeutic dosing in high‑risk patients, measure anti‑Xa only if clinically significant bleeding occurs or drug accumulation is suspected【23】【24】.
• When monitoring, obtain a sample 4–6 hours after the third or fourth dose (steady‑state condition)【22】.

Duration of Therapy

• Continue enoxaparin throughout the hospital stay, up to a maximum of 8 days, or until a definitive intervention (e.g., surgery) is performed【21】.
• The 8‑day limit is supported by Level A evidence from the ESSENCE and TIMI‑11B trials【21】.

Alternative Anticoagulants When Enoxaparin Is Contraindicated

Critical Safety Considerations (Errors to Avoid)

• Do NOT use the standard twice‑daily therapeutic regimen in patients with CrCl < 30 mL/min; it markedly increases major bleeding without added benefit【23】.
• Do NOT give an IV bolus of 30 mg to patients ≥ 75 years; use the reduced SC regimen to lower age‑related bleeding risk【21】.
• Do NOT extend enoxaparin therapy beyond 8 days without transitioning to an oral anticoagulant, to prevent heparin‑induced thrombocytopenia【21】.

All statements are derived from peer‑reviewed sources and guideline societies as indicated by the citation IDs.

Enoxaparin Dosing Adjustments and Alternatives in Renal Impairment and Special Populations

VTE Prophylaxis Dosing Adjustments

• In hospitalized surgical patients, a prophylactic regimen of 30 mg subcutaneously every 12 hours provides efficacy comparable to the standard 40 mg once‑daily schedule, supporting its use when twice‑daily dosing is preferred【25】【26】.
• For patients with extreme obesity (BMI ≥ 40 kg/m² or weight > 150 kg), a prophylactic dose of 40 mg subcutaneously every 12 hours may be required to achieve adequate anticoagulation, without the need for routine anti‑Xa monitoring【25】.

Therapeutic Dosing and Renal Safety

• In individuals with severe renal impairment (CrCl < 30 mL/min), maintaining the standard twice‑daily therapeutic dose (1 mg/kg every 12 h) increases major bleeding risk by 3.9‑fold (OR 3.88; 95 % CI 1.78–8.45) without improving thrombotic efficacy【27】.
• Reducing the therapeutic regimen to a once‑daily dose (1 mg/kg once daily) in the same renal population eliminates the excess bleeding risk (OR 0.58; 95 % CI 0.09–3.78)【27】.

Alternative Anticoagulants for Renal Dysfunction

• Unfractionated Heparin (UFH) does not accumulate in renal dysfunction and is preferred when rapid reversibility is required【27】. Recommended dosing: 60–80 U/kg IV bolus followed by 12–18 U/kg/h infusion, titrated to an aPTT of 1.5–2.0 × control【27】.
• Dalteparin offers a renal‑safe option: a prophylactic dose of 5,000 IU once daily does not bio‑accumulate in patients with CrCl < 30 mL/min【27】; therapeutic dosing can be 200 IU/kg once daily or 100 IU/kg every 12 hours【27】.
• Fondaparinux is contraindicated in CrCl < 30 mL/min【27】. For patients with adequate renal function (CrCl ≥ 30 mL/min), weight‑based dosing is:
  
  • < 50 kg → 5 mg daily
  • 50–100 kg → 7.5 mg daily
  • > 100 kg → 10 mg daily【27】.
• During percutaneous coronary intervention (PCI), fondaparinux must be combined with UFH to prevent catheter‑related thrombi【28】.

Risk Stratification for Urologic Surgery

Post‑Discharge Prophylaxis Considerations

• For very high‑risk patients (e.g., after major cancer surgery or prolonged immobility), extending enoxaparin prophylaxis beyond hospitalization may be appropriate, guided by individual risk assessment【25】【26】.

Enoxaparin Dose Adjustment in Severe Renal Impairment for Acute Pulmonary Embolism

Dose Reduction for Enoxaparin

• In patients with acute pulmonary embolism and creatinine clearance < 30 mL/min, the therapeutic enoxaparin regimen should be reduced to 1 mg/kg subcutaneously once daily (a 50 % reduction of the total daily dose) rather than the standard twice‑daily schedule. 29

Preferred Alternative When Enoxaparin Is Contraindicated

• Unfractionated heparin (UFH) does not accumulate in renal dysfunction and is the preferred alternative when rapid reversibility or hemodynamic instability is required; recommended dosing is an IV bolus of 80 U/kg followed by an infusion of 18 U/kg/h, titrated to maintain an aPTT of 1.5–2.0 × control. 29

Contraindicated Anticoagulant

• Fondaparinux is contraindicated in patients with creatinine clearance < 30 mL/min and should not be used under any circumstances. [29][30]

Transition to Oral Anticoagulation

• After the initial parenteral phase, patients should be transitioned to an oral anticoagulant for long‑term management; direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban can be used without a loading parenteral dose, whereas dabigatran and edoxaban require prior parenteral anticoagulation. In individuals with creatinine clearance < 30 mL/min, DOACs are generally contraindicated or require substantial dose adjustments, so warfarin with INR monitoring is the preferred oral agent. [29][30]

Enoxaparin Use, Contraindications, and Preferred Alternatives in Acute Myocardial Infarction

Renal Impairment and Bleeding Risk

• In patients with moderate‑to‑severe renal dysfunction (creatinine clearance < 30 mL/min), enoxaparin is associated with a markedly higher incidence of major bleeding; therefore it should be avoided whenever possible【31】【32】.
• If enoxaparin must be administered in this population, the dose should be reduced to 1 mg/kg once daily (instead of the standard twice‑daily regimen)【32】【33】.
• Unfractionated heparin (UFH) is the preferred anticoagulant in severe renal impairment because it does not accumulate and can be rapidly reversed with protamine【32】.

High‑Risk Bleeding Situations (Non‑Absolute Contraindications)

• Recent intracranial hemorrhage or stroke constitutes a high‑risk scenario for enoxaparin use; clinical judgment should favor alternative anticoagulation【31】【32】.
• The EXTRACT‑TIMI trial reported increased major bleeding (including fatal bleeding) with enoxaparin in patients who had recent intracranial events, although intracerebral hemorrhage was not observed【31】【32】.
• Severely uncontrolled hypertension (systolic > 180 mmHg) raises the risk of hemorrhagic complications; blood pressure should be controlled before initiating enoxaparin【31】【32】.

Anticoagulant Switching and Bleeding

• Switching between enoxaparin and UFH during active treatment significantly increases the risk of major bleeding【33】【34】【35】.
• The SYNERGY trial demonstrated higher bleeding rates in patients who crossed over between anticoagulants【34】.
• Guidance: once enoxaparin is started, continue it unless a compelling indication mandates a switch to UFH【33】.

Dosing Adjustments in Elderly Patients with Renal Dysfunction

• Patients aged ≥ 75 years with creatinine clearance < 30 mL/min require dose reduction to 0.75 mg/kg subcutaneously every 12 h (or 1 mg/kg once daily if CrCl < 30 mL/min)【33】【36】.
• In those ≥ 75 years receiving fibrinolytic therapy, the initial IV bolus of enoxaparin should be omitted【33】【36】.

Contraindication of Fondaparinux in Severe Renal Failure

• Fondaparinux is absolutely contraindicated when creatinine clearance is < 30 mL/min【35】.

Preferred Alternative Anticoagulants

Unfractionated Heparin (UFH)

• UFH is recommended as the alternative anticoagulant in patients with renal dysfunction, active bleeding risk, or when rapid reversibility is required【32】【35】.
• Typical dosing: 60–80 U/kg IV bolus followed by an infusion of 12–18 U/kg/h, titrated to an activated partial thromboplastin time of 1.5–2.0 × control【35】.
• UFH does not accumulate in renal failure and can be promptly reversed with protamine【32】.

Bivalirudin

• For patients with a history of heparin‑induced thrombocytopenia (HIT), bivalirudin is the preferred alternative anticoagulant【35】【36】.
• In renal impairment (CrCl < 30 mL/min), the bivalirudin infusion rate should be reduced to 1.0 mg/kg/h【35】.
• A 2025 Circulation study showed that bivalirudin with post‑PCI infusion yielded superior outcomes compared with UFH in STEMI patients undergoing primary PCI【36】.

Fondaparinux (when renal function is adequate)

• Fondaparinux 2.5 mg subcutaneously once daily is an option for patients with creatinine clearance ≥ 30 mL/min【35】【36】.
• During PCI, an adjunctive UFH infusion is required to prevent catheter‑related thrombosis when fondaparinux is used【35】【36】.

All statements are derived from peer‑reviewed sources indicated by the citation IDs. Strength of evidence ranges from randomized trial data (e.g., EXTRACT‑TIMI, SYNERGY, 2025 Circulation study) to guideline‑based recommendations.